12 results about "Lansoprazole" patented technology

The invention relates to the field of biological medicine, in particular to novel application of lansoprazole. The invention discloses application of lansoprazole to preparation of a medicine for treating breast cancer by inhibiting an FASN target spot to act on breast cancer stem cells. The lansoprazole is applied to preparation of the anti-breast cancer medicine by inhibiting expression of FASN and depletion of CD8 + T cells and remodeling a breast cancer immune microenvironment. And a basis is provided for clinical transformation of lansoprazole'new use of old medicine '.

The invention relates to the field of biological medicines, in particular to application of fatty acid synthase (FASN) as a target spot in screening or preparing medicines for treating breast cancer, and particularly relates to targeted therapy for breast cancer stem cells (BCSCs). The invention discloses application of an FASN target spot in screening or preparing a medicine for treating breast cancer. Research finds that FASN is highly expressed in BCSCs, and stem cell characteristics of the BCSCs are maintained by activating a Wnt / beta-catenin pathway. By inhibiting the activity of FASN (such as using lansoprazole), the proliferation, self-renewal and tumor formation ability of BCSCs can be significantly reduced. The invention provides an FASN-based drug screening method and a drug composition, and provides a new strategy for breast cancer treatment.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The present application provides a method for quantitatively analyzing acid-suppressing drugs by a high-performance liquid chromatography-tandem mass spectrometry device, comprising: preparing a sample solution containing the acid-suppressing drug; injecting the sample solution into the high-performance liquid chromatography-tandem mass spectrometry device to obtain a mass chromatogram; and quantitatively analyzing the acid-suppressing drug using an internal standard method according to the mass chromatogram, wherein the acid-suppressing drug is selected from: esomeprazole, rabeprazole, ilaprazole, lansoprazole, pantoprazole and vonoprazan fumarate; using a mixed mobile phase consisting of mobile phase A and mobile phase B for gradient elution in the high-performance liquid chromatography, wherein mobile phase A is an acetonitrile solution containing formic acid or a water-acetonitrile mixture containing ammonia and ammonium acetate (water: acetonitrile volume ratio: 1:99-10:90); and mobile phase B is selected from an aqueous solution containing ammonium acetate, an aqueous solution containing formic acid and ammonium acetate, an aqueous solution containing ammonia and ammonium acetate, and an aqueous solution containing ammonia and ammonium formate.

The application belongs to the technical field of pharmaceutical analysis, and particularly discloses a method for determining acid resistance of lansoprazole enteric-coated capsules and application thereof.The method for determining acid resistance of lansoprazole enteric-coated capsules first adopts a reciprocating cylinder method to perform acid dissolution on the content of lansoprazole enteric-coated capsules, and then adopts a high performance liquid chromatography method to determine the residual content of lansoprazole in the content after acid resistance; the acid-dissolved acid-resistant medium is an acetate buffer solution containing an anionic surfactant, and the pH value of the acetate buffer solution is 4.5.The acid resistance determination method has strong in-vitro and in-vivo correlation, and can effectively improve the success rate of in-vitro evaluation of bioequivalence of generic drugs and reference preparations.

The application belongs to the technical field of bioengineering, and relates to a thioether monooxygenase mutant, a nucleic acid for coding the thioether monooxygenase mutant, a recombinant expression vector containing the nucleic acid, a recombinant expression transformant containing the recombinant expression vector, and application of the recombinant thioether monooxygenase mutant in preparation of a chiral lansoprazole medicine. Compared with other biological catalysts for preparing optically pure lansoprazole medicines, the thioether monooxygenase mutant provided by the application has the advantages of high protein expression amount, high catalytic activity, strong solvent tolerance, good thermal stability, high optical purity of a product, and high yield, and shows a wide application prospect in industrial application.

The application discloses a content detection method of lansoprazole composition and belongs to the field of medicine detection. The content of lansoprazole composition is detected by using high performance liquid chromatography. The detection conditions of high performance liquid chromatography are limited, octadecylsilane bonded silica gel is used as a chromatographic column, water-acetonitrile-triethylamine is used as a mobile phase, and isocratic elution is carried out. The content of lansoprazole composition can be accurately detected, and the detection method has high precision.

The present application provides a polycyclic ketone monooxygenase mutant, the amino acid sequence of which is obtained by mutation of the amino acid sequence shown in SEQ ID NO. 2, and discloses a method for asymmetric biocatalytic synthesis of a lrazole drug based on the mutant. The enzyme catalyst developed based on the present application can be used to asymmetrically catalyze the synthesis of (R)-rabeprazole, lansoprazole and other lrazole compounds under mild conditions using a whole cell or enzyme protein catalytic method, without the need for chemical catalysts, and is environmentally friendly, being a green biocatalytic synthesis route.

This invention provides a lansoprazole sustained-release tablet, comprising a tablet core and a coating layer. The tablet core includes sustained-release granules, immediate-release granules, and other pharmaceutically acceptable excipients. The coating layer is made of enteric-coated film-coating powder. The lansoprazole sustained-release tablet provided by this invention provides rapid onset of action and maintenance of blood drug concentration upon oral administration, high bioavailability, and few side effects. It improves the solubility of lansoprazole, eliminating the need for surfactant solubilization. It also exhibits high acid stability, eliminating the need for an isolation coating. The lansoprazole sustained-release tablet of this invention employs a two-stage granulation method, both of which are dry granulation, separately preparing sustained-release and immediate-release granules. This avoids the high-temperature drying process following traditional wet granulation, thus improving the stability of lansoprazole.

The invention belongs to the field of medicines, and discloses a dexlansoprazole pharmaceutical composition, which comprises an enteric quick-release pellet and an enteric slow-release pellet, the enteric quick-release pellet sequentially comprises a drug application pellet, an isolation layer and an enteric quick-release layer from inside to outside, and the enteric slow-release pellet sequentially comprises the drug application pellet, the isolation layer and the enteric slow-release layer from inside to outside; the enteric coating material of the enteric quick-release pellet is selected from Eudragit L30D-55, Eudragit L30D-65, hydroxypropyl methyl cellulose phthalate or polyacrylic resin latex solution, and the enteric coating material of the enteric quick-release pellet is selected from Eudragit L30D-55, Eudragit L30D-65, hydroxypropyl methyl cellulose phthalate or polyacrylic resin latex The enteric-coated slow-release layer is made of Eudragit S100, the enteric-coated slow-release layer is prepared by taking water as a solvent, preparing the enteric-coated slow-release material into a slow-release enteric-coated layer coating solution and then adopting a fluidized bed bottom spraying coating process, and a stabilizer is added when the slow-release enteric-coated layer coating solution is prepared. No organic solvent is adopted in the preparation process, and industrial large-scale production is facilitated.

The invention relates to the technical field of freeze-dried powder preparation, and provides a lansoprazole freeze-dried powder injection preparation device and a preparation method thereof.The device comprises a machine body shell, a freeze-drying cabin is formed in the machine body shell, an adjusting structure and a temperature control structure are arranged in the machine body shell, and the temperature control structure comprises a heating system, a cooling system and a vacuum system; a supporting plate is arranged in the freeze-drying cabin, a bearing plate is borne on the surface of the upper end of the supporting plate, and a control panel is fixedly connected to the outer surface of the machine body shell. Wherein the heating system is used for heating the interior of the freeze-drying cabin, and the heating system comprises a heating pipe fixedly connected to the surface of the inner wall of the machine body shell; and the cold supply system is used for cooling the interior of the freeze-drying cabin. By means of the technical scheme, the problems that due to the fact that an existing freeze-dried powder injection preparation device cannot evenly and effectively conduct freeze-drying during freeze-drying, local freeze-drying is completed, local freeze-drying is not completed, and the overall freeze-drying time is prolonged are solved.

The invention relates to a molybdenum catalyst and a preparation method and application thereof. The method comprises the following steps: by taking ammonium heptamolybdate as a molybdenum source, trithiocyanuric acid as a sulfur source and activated carbon as a carrier, dispersing by ball milling, and calcining and loading in a nitrogen atmosphere to obtain the catalyst with molybdenum disulfide loaded on the activated carbon. The catalyst can be recovered through centrifugation and filtration and has excellent cycle stability. According to the method, a dexlansoprazole by-product (a mixture mainly containing levolansoprazole) is taken as a substrate, under the action of a molybdenum catalyst, hydrogen is introduced as a reducing agent, and the by-product can be reduced into the lansoprazole thioether (a synthetic precursor of dexlansoprazole) in a high-selectivity manner. In addition, racemic lansoprazole can be directly used as a substrate, high-selectivity reduction into lansoprazole thioether (a dexlansoprazole synthesis precursor) can be realized under the action of the same molybdenum catalyst, and the raw material application range of the process is further widened. The method solves the industrial problem that byproducts cannot be efficiently recycled in the existing dexlansoprazole synthesis process, has the advantages of simple reaction process, easiness in product separation and catalyst recyclability, and has a good industrial application prospect.